Senzime Dirección

Dirección controles de criterios 3/4

El CEO de Senzime es Philip Siberg , nombrado en May 2023, tiene una permanencia de 1.5 años. compensación anual total es SEK4.61M, compuesta por 55.2% salario y 44.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.62% de las acciones de la empresa, por valor de €350.32K. La antigüedad media del equipo directivo y de la junta directiva es de 2.8 años y 3.7 años, respectivamente.

Información clave

Philip Siberg

Chief Executive Officer (CEO)

SEK 4.6m

Compensación total

Porcentaje del salario del CEO	55.2%
Permanencia del CEO	1.5yrs
Participación del CEO	0.6%
Permanencia media de la dirección	2.8yrs
Promedio de permanencia en la Junta Directiva	3.7yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Philip Siberg en comparación con los beneficios de Senzime?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-SEK 131m
Jun 30 2024	n/a	n/a	-SEK 130m
Mar 31 2024	n/a	n/a	-SEK 131m
Dec 31 2023	SEK 5m	SEK 3m	-SEK 134m
Sep 30 2023	n/a	n/a	-SEK 138m
Jun 30 2023	n/a	n/a	-SEK 137m
Mar 31 2023	n/a	n/a	-SEK 143m
Dec 31 2022	SEK 450k	n/a	-SEK 133m
Sep 30 2022	n/a	n/a	-SEK 114m
Jun 30 2022	n/a	n/a	-SEK 104m
Mar 31 2022	n/a	n/a	-SEK 86m
Dec 31 2021	SEK 400k	n/a	-SEK 82m
Sep 30 2021	n/a	n/a	-SEK 74m
Jun 30 2021	n/a	n/a	-SEK 66m
Mar 31 2021	n/a	n/a	-SEK 56m
Dec 31 2020	SEK 100k	n/a	-SEK 47m
Sep 30 2020	n/a	n/a	-SEK 41m
Jun 30 2020	n/a	n/a	-SEK 36m
Mar 31 2020	n/a	n/a	-SEK 32m
Dec 31 2019	SEK 100k	n/a	-SEK 33m
Sep 30 2019	n/a	n/a	-SEK 34m
Jun 30 2019	n/a	n/a	-SEK 33m
Mar 31 2019	n/a	n/a	-SEK 30m
Dec 31 2018	SEK 100k	n/a	-SEK 24m
Sep 30 2018	n/a	n/a	-SEK 19m
Jun 30 2018	n/a	n/a	-SEK 16m
Mar 31 2018	n/a	n/a	-SEK 13m
Dec 31 2017	SEK 131k	n/a	-SEK 13m

Compensación vs. Mercado: La compensación total ($USD417.82K) de Philip está en línea con el promedio de empresas de tamaño similar en el mercado German ($USD471.14K).

Compensación vs. Ingresos: La compensación de Philip ha aumentado mientras la empresa no es rentable.

CEO

Philip Siberg (51 yo)

1.5yrs

Permanencia

SEK 4,614,088

Compensación

Mr. Philip Siberg serves as the Chief Executive Officer of Stille Surgical, Inc. He serves as Chairman of the Board at Acarix AB (publ) since May 11, 2021. He was Co-Founder of Coala-Life Group AB (publ) a...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Philip Siberg	Chief Executive Officer	1.5yrs	SEK 4.61m	0.62% € 350.3k
Slavoljub Grujicic	Chief Financial Officer	2.8yrs	sin datos	0.022% € 12.4k
Johanna Tulkki	Chief Operating Officer	4.8yrs	sin datos	sin datos
Fredrik Norrby	Chief Technology Officer	1.8yrs	sin datos	sin datos
Rianne Waninge	Application Scientist	no data	sin datos	sin datos
Paula Treutiger	Head of Communication & Investor Relations	2.8yrs	sin datos	sin datos
Anders Selin	Executive Vice President of Sales	5.2yrs	sin datos	sin datos
Michael Noble	Vice President Global Marketing	less than a year	sin datos	sin datos
Anders Jacobson	Chief Innovation Officer	8.8yrs	sin datos	0.014% € 7.9k
Catrin Molund	Executive Vice President of Business Development	3.8yrs	SEK 163.00k	sin datos
Johanna Faris	Head of Q/RA/S	less than a year	sin datos	0.0014% € 776.6

2.8yrs

Permanencia media

54yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 6YC se considera experimentado (2.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Per Wold-Olsen	Chairman of the Board	less than a year	sin datos	0.56% € 316.0k
Goran Brorsson	Independent Director	1.5yrs	SEK 131.00k	0.090% € 50.4k
Adam Dahlberg	Vice Chairman of the Board	24.8yrs	SEK 350.00k	5.55% € 3.1m
Eva Walde	Independent Director	3.7yrs	SEK 210.00k	sin datos
Sorin Brull	Chief Medical Officer	8.8yrs	SEK 1.31m	3.33% € 1.9m
Alfredo Abad-Gurumeta	Member of Scientific Advisory Board	no data	sin datos	sin datos
Bela Fulesdi	Member of Scientific Advisory Board	no data	sin datos	sin datos
Guy Cammu	Member of Scientific Advisory Board	no data	sin datos	sin datos
Hans Boer	Member of Scientific Advisory Board	no data	sin datos	sin datos
Claude Meistelman	Member of Scientific Advisory Board	no data	sin datos	sin datos
Jennifer Hunter	Member of Scientific Advisory Board	no data	sin datos	sin datos
Casper Claudius	Member of Scientific Advisory Board	no data	sin datos	sin datos

3.7yrs

Permanencia media

68yo

Promedio de edad

Junta con experiencia: La junta directiva de 6YC se considera experimentada (3.7 años de antigüedad promedio).

Senzime Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Chairman of the Board recently bought €106k worth of stock

Less than half of directors are independent

Senzime AB (publ) Announces Board Changes

Less than half of directors are independent

Senzime AB (Publ) Appoints Philip Siberg as Chief Executive Officer

Less than half of directors are independent

Recent updates

Chairman of the Board recently bought €106k worth of stock

New minor risk - Profitability

Third quarter 2024 earnings released: kr0.26 loss per share (vs kr0.33 loss in 3Q 2023)

Senzime AB (publ) to Report Q1, 2025 Results on May 07, 2025

Senzime Successfully Unveils Next-Generation TetraGraph Quantitative Train-Of-Four Monitor at ANESTHESI Technology 2024

Senzime to Launch Next-Generation Tetragraph System At Anesthesiology 2024 Conference

Second quarter 2024 earnings released

Senzime AB (publ.) Announces European Patent Office Issues New Patent Protecting Unique Capabilities of the Senzime TetraGraph System

New minor risk - Profitability

Full year 2023 earnings released: kr1.45 loss per share (vs kr1.99 loss in FY 2022)

Senzime AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

Full year 2023 earnings released: kr1.45 loss per share (vs kr1.99 loss in FY 2022)

Less than half of directors are independent

Senzime AB (publ) Announces Board Changes

Senzime Announces New Clinical Study with the Tetragraph System Published in the British Journal of Anesthesia Open

Third quarter 2023 earnings released: kr0.33 loss per share (vs kr0.74 loss in 3Q 2022)

Senzime AB (publ) to Report Fiscal Year 2023 Results on Feb 15, 2024

New major risk - Shareholder dilution

Senzime Launches Tetras Sensitive, the Market's First Sensor for Nemomuscular Monitoring of Patients with Sensitive Skin

No longer forecast to breakeven

Senzime AB (publ) Announces New Study Valued the Feasibility of TetraSens Pediatric Disposable Sensor

Senzime AB (publ) Presents Scientific Study at Euroanaesthesia 2023 and Validates New TetraGraph Electromyographic Detection Algorithm

Less than half of directors are independent

No longer forecast to breakeven

Senzime AB (Publ) Appoints Philip Siberg as Chief Executive Officer

First quarter 2023 earnings released: kr0.42 loss per share (vs kr0.33 loss in 1Q 2022)

Less than half of directors are independent

Independent Chairman recently bought €66k worth of stock

Less than half of directors are independent

Senzime Receives Approval for Its Pediatric Sensor in Japan

Full year 2022 earnings released: kr1.99 loss per share (vs kr1.31 loss in FY 2021)

Senzime AB (publ) to Report Q3, 2023 Results on Oct 26, 2023

Senzime AB (publ) to Report Fiscal Year 2022 Results on Feb 01, 2023

Senzime Receives First Contract for TetraSens Pediatric in the US

Less than half of directors are independent

Senzime's TetraGraph supported by new European clinical guidelines for patient monitoring

Senzime AB (publ) Provides Earnings Guidance for 2025

Senzime AB (Publ) Announces Board Appointments

Senzime AB (publ) Receives FDA 510K-Clearance for New Disposable Sensor Intended for Monitoring of Children

Senzime AB (publ) Announces Launch of TetraGraph Xcom Interface to Electronic Medical Records

Forecast breakeven date pushed back to 2024

Second quarter 2022 earnings released: kr0.63 loss per share (vs kr0.35 loss in 2Q 2021)

Less than half of directors are independent

Senzime AB (publ) (OM:SEZI) entered into an agreement to acquire Respiratory Motion, Inc. for $44 million.

First quarter 2022 earnings released: kr0.33 loss per share (vs kr0.27 loss in 1Q 2021)

Less than half of directors are independent

Senzime AB (Publ) Applies for FDA Approval for A New Single-Use Sensor for Children

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Senzime Announces Anesthesia Patient Safety Foundation Recommends Use of A Quantitative Monitor Whenever A Neuromuscular Blocking Agent Is Administered

Senzime AB (Publ) Announces Japanese Study Confirms Tetragraph Monitor as a Better Indicator of Appropriate Reversal Dose of Sugammadex and Adequate Recovery of Neuromuscular Function Than Amg-Based Tof- Watch SX

Third quarter 2021 earnings released: kr0.31 loss per share (vs kr0.20 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.35 loss per share (vs kr0.23 loss in 2Q 2020)

First quarter 2021 earnings released: kr0.27 loss per share (vs kr0.17 loss in 1Q 2020)

Senzime AB (publ) Appoints Eva Walde as New Member of the Board of Directors

Full year 2020 earnings released: kr0.84 loss per share (vs kr0.68 loss in FY 2019)

Senzime AB (publ) to Report Q3, 2021 Results on Nov 12, 2021

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad